The pharmaceutical company behind the life-saving EpiPen allergy injection may have overcharged the federal government by more than $1 billion.
The Department of Health and Human Services wrote a letter to Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, to inform the committee that Mylan may have swindled $1.27 billion from taxpayers over the past 10 years.
Mylan is accused of incorrectly classifying the EpiPen as a generic drug instead of a brand name. This allowed the company to provide Medicaid less in rebates. Taxpayers ended up with a bigger bill.
Mylan is in the process of finalizing a $465 million settlement with the Department of Justice over the misclassification.